Background The effects of smoking and smoking cessation on lipoproteins have not been studied in a large contemporary group of smokers. This study was designed to determine the effects of smoking cessation on lipoproteins.
Background
Each year, smoking contributes to N443,000 smokingrelated deaths in the United States 1 ; and nearly 20% of all coronary heart disease deaths can be attributed to smoking. 1, 2 Although the strong relationship between smoking and cardiovascular disease (CVD) has been welldocumented, 3, 4 the mechanisms by which smoking increases CVD risk appear to be multifactorial and incompletely understood, in part because these associations have been derived from observational studies. [5] [6] [7] [8] These studies, and smaller clinical trials, suggest that cigarette smoking is associated with a more atherogenic lipid profile 6, 8, 9 characterized by higher total cholesterol and triglycerides (TG) with lower levels of high-density lipoprotein cholesterol (HDL-C).
Smoking intensity also has been associated with small, statistically significant increases in low-density lipoprotein cholesterol (LDL-C) and decreases in HDL-C. 6, 8, 10 Some have described small dense LDL particles among current smokers and improvements in lipids after smoking cessation; however, these findings have been less consistent. 11, 12 No studies, to date, have prospectively evaluated the effects of continued smoking and smoking cessation on lipoproteins in a large, contemporary cohort of current smokers. This is a matter of considerable importance because smokers in the 21st century are significantly more overweight than those studied previously. 6, 8, 13 Because smoking cessation is associated with weight gain [14] [15] [16] and weight gain affects lipoproteins, 8, 17, 18 the effects of smoking cessation on lipoproteins remain unclear.
We evaluated the effects of current smoking and smoking cessation on lipids and lipoproteins in a prospective, randomized clinical trial of smoking cessation pharmacotherapy. 19 
Methods

Study participants and design
All subjects provided informed consent. Subjects were participants in a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of smoking cessation pharmacotherapies and to examine the natural history of continued smoking and smoking cessation on CVD risk (clinicaltrials.gov registration no. NCT00332644). 19 Specific recruitment strategies have been described previously. 19 This article describes the effects of smoking cessation and continued smoking on lipids and lipoprotein subfractions 1 year after the target quit date, a prespecified analysis in this study. The authors are solely responsible for the design and conduct of this study; all study analyses, the drafting and editing of the paper, and its final contents.
Participants were randomized to 1 of 6 treatment conditions: nicotine lozenge, nicotine patch, sustained-release bupropion, nicotine patch plus nicotine lozenge, sustained-release bupropion plus nicotine lozenge, or placebo. 19 All participants received individual cessation counseling. 19 Major inclusion criteria were age ≥18 years, smoking ≥10 cigarettes per day, expired carbon monoxide (CO) level N9 ppm, and stated motivation to quit smoking. Exclusion criteria have been reported previously 19 ; the major ones were blood pressure (BP) N160/100 mm Hg, recent myocardial infarction, heavy alcohol use, use of contraindicated medications, and current pregnancy or breast-feeding.
Study procedures
Subjects were recruited from communities in and around Madison and Milwaukee, WI, from January 2005 to June 2007. 19 The baseline clinical trial visits included measurement of anthropometric data, fasting laboratory tests, and completion of questionnaires and interviews. Baseline physical activity was assessed by the International Physical Activity Questionnaire. 20 Baseline alcohol use was measured as alcoholic drinks consumed per month. 21 Smoking burden was evaluated by current cigarette smoking (cigarettes per day) and pack-years (current cigarettes per day ⁎ years smoked). Recent smoke exposure was measured by an exhaled CO level, which reflects smoking efficiency and recent smoke exposure. Smoking status was assessed by self-reported 7-day point-prevalence abstinence using a smoking calendar and the timeline follow-back method, confirmed by an exhaled CO level of b10 ppm (Micro-3 Smokerlyzer; Bedfont Scientific, Williamsburg, VA).
21,22
Measurement of lipids and lipoproteins
Fasting blood samples were obtained by venipuncture and refrigerated. Plasma aliquots were isolated by centrifugation and frozen at −70°C. Samples underwent nuclear magnetic resonance spectroscopic lipoprotein analysis (Lipoprofile-2; LipoScience, Inc, Raleigh, NC) using previously published methods. 23 , and small HDL (7.3-8.2 nm). Total LDL particle concentrations are the sum of the IDL, large LDL, and small LDL subclass concentrations. Total HDL particle concentrations are the sum of large, medium, and small HDL subclass concentrations. Weighted-average LDL and HDL particle sizes were determined by summing the diameter of each subclass multiplied by its relative mass percentage as estimated by the amplitude of its methyl nuclear magnetic resonance signal. 23, 24 Nuclear magnetic resonance-derived cholesterol and TG were determined by conversion of lipoprotein particle data to lipid concentration units (in milligrams per deciliter) based on the expected amount of cholesterol and TG in each particle. 23 
Statistical analysis
All analyses were conducted using PASW Statistics 18 software (SPSS Inc, Chicago, IL). Means (SDs) were determined for the subject characteristics and smoking intensity parameters in Table I . Variable disributions were evaluated for normality. Skewed variables (TG, alcohol consumption, and International Physical Activity Questionnaire activity scores) were logtransformed. Pearson correlations were used to identify univariate associations between age, sex, body mass index (BMI), waist circumference, weight, glucose, baseline cigarettes per day, baseline physical activity, and baseline alcohol use with lipids and lipoproteins at baseline and after 1 year. Changes were computed by subtracting year 1 from baseline values. t Tests were used to compare change scores for BMI, weight, waist circumference, glucose, CO levels, and the lipid and lipoprotein measures between participants who were abstinent at 1 year and those who were smoking.
Multivariable linear regression models were constructed to determine associations of changes in lipids and lipoproteins from baseline to 1 year after the target quit date. Separate models were created for predicting changes in each lipid fraction hypothesized to be influenced by smoking status (HDL-C, LDL-C, and TG) and selected lipoprotein measures chosen because of established relationships with smoking and/or CVD risk (total LDL particles, small LDL particles, LDL size, total HDL particles, large HDL particles, HDL size). Because there were 9 lipid and lipoprotein variables of interest, a Bonferroni-corrected α b .0056 was used to control for type I error. For other variables, a standard α b .05 was used. Each model was adjusted for baseline values of each lipid or lipoprotein parameter. All models included covariates that could affect the dependent variables independently of smoking cessation, such as age, sex, race, weight change, treatment arm, baseline cigarettes per day, baseline physical activity, baseline alcohol consumption, smoking status at year 1 (abstinent or continued smoker), and change in glucose level. Change in weight was used rather than change in BMI or waist circumference because it had the strongest univariate associations with changes in the lipoprotein parameters. Multivariable models are described using R 2 values and β coefficients. Partial regression plots of change in HDL-C by quartile of baseline cigarettes per day and quintile of baseline CO (adjusted for change in weight and baseline HDL-C) also were examined to determine if changes in HDL-C among abstainers were related to baseline smoking intensity. HL07936 from the National Heart, Lung, and Blood Institute. Dr Baker was supported by grant K05CA139871 from the National Cancer Institute. Medications were provided by GlaxoSmithKline (Philadelphia, PA). The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents.
Results
Subject characteristics
Subject characteristics at baseline and year 1 are provided in Table I . There were 1,504 smoking subjects randomized. As often observed in smoking cessation clinical trials, [25] [26] [27] 581 (39%) subjects did not return for their 1-year follow-up visit. Individuals who returned for this visit were slightly older (mean 1.2 years, P b .001) and had slightly higher HDL-C (mean 1.4 mg/dL, P = .041) than those who did not return, but otherwise had similar CO levels, waist circumference, serum glucose, total cholesterol, TG, LDL-C, and high-sensitivity C-reactive protein (all Ps N .20). 15, 28 Of the 923 subjects who attended the year 1 visit, 58% were women, 84% were white, and 13% were African American. Abstinence from smoking was confirmed in 334 (36.2%) participants. Only 5% were using lipidlowering medications. Excluding these subjects did not change the results significantly (data not shown). Only 2.8% of subjects had hemoglobin A 1 C N7%; 14. Table I) .
Effects of smoking cessation
Comparisons between abstainers and continuing smokers are summarized in Table I . After 1 year, CO levels decreased in both abstainers and continued smokers; however, subjects who abstained had significantly greater CO reductions (−21.3 [11.2] (Figure 1) . Statistically significant differences in other lipid and lipoprotein fractions were not observed.
Independent associations with change in HDL parameters
Models to identify independent predictors of changes in HDL-C and particles are described in Table II . All analyses were adjusted for baseline values of each lipid or lipoprotein parameter, as well as the parameters described in the "Methods." As expected, the most powerful predictors of changes in the HDL-related parameters were baseline values, with larger changes among those with the lowest baseline levels of HDL-C, total HDL particles, and large HDL particles and the smallest HDL diameters. For HDL-C, total HDL particles, and large HDL particles, the next most powerful predictors were abstinence from smoking and female sex, except for HDL particle size, for which change in weight was nearly as powerful a predictor as baseline HDL diameter. In abstainers, neither baseline number of cigarettes smoked per day (P = .834) nor baseline CO levels (P = .107) predicted changes in any HDL-related parameter after adjustment for changes in weight and baseline HDL-C.
Discussion
To our knowledge, this is the largest prospective, randomized clinical trial that has evaluated the effects of smoking cessation on lipid and lipoprotein levels. Although smoking is associated with low HDL-C, previous studies suggesting that smoking cessation increases HDL-C levels were from older, observational studies with less contemporary cohorts or from smaller clinical trials. Smokers in our study had higher BMIs than in previous reports and are more representative of the current United States population. 6, 8, 9, 13, 29 Despite our subjects being more overweight and gaining weight after smoking cessation, we showed that smoking cessation was related to higher HDL-C and higher total and large HDL particles. Patients with the lowest HDLrelated parameters had the largest increases in HDL. After baseline levels of HDL-C and HDL particles, abstinence from cigarette smoking was the next most powerful predictor of changes in these parameters, followed by female sex and weight change. The observation that women had larger increases in HDL-C and HDL particles after smoking cessation is consistent with our previous observation that, among current smokers, the association between pack-years of smoking and the presence of carotid plaque was stronger in women 30 and a previous observation that smoking has a stronger association with coronary heart disease incidence in women compared with men. 31 The mechanisms by which smoking decreases HDL-C are incompletely understood. Smoking increases catecholamine release, causing a surge in circulating free fatty acids, which may increase VLDL and LDL concentrations and reduce HDL-C concentrations. 8 Smoking reduces lecithin-cholesterol acyltransferase, the enzyme responsible for esterifying free cholesterol and increasing HDL size, 32 and may reduce levels of cholesterol ester transfer protein; however, studies of the effects of smoking on these enzymes have had mixed results. [33] [34] [35] In population-based studies, a 1-mg/dL increase in HDL-C has been associated with a 2% to 3% decrease in CVD events. 36, 37 This implies that, in our subjects, smoking abstinence could reduce CVD events by 4% to 6% over a decade. Our study also suggests that abstinence from smoking is associated with increases in HDL-C, regardless of baseline smoking intensity. This important finding may encourage clinicians to emphasize abstinence even in light smokers.
Weight gain after smoking cessation can be a significant barrier to quitting. [14] [15] [16] In our study, those who abstained gained approximately 4 kg more than those who resumed smoking. Increased weight has been associated with lower HDL-C, such that every kilogram of additional weight can reduce HDL-C by 0.5% to 1% 17, 18 ; however, HDL-C increased by 5.2% among abstainers in our study. Weight gain was independently associated with increased HDL-C as well as total and large HDL particles. This suggests that the impact of weight gain on HDL may be counteracted by the impact of smoking cessation. This important finding has not been reported previously in a cohort of this size. Smoking has been associated with increased TG. 6 In our study, abstinence from smoking was associated with only mild TG reductions that were not statistically significant after correcting for multiple comparisons, likely because of the counterbalancing effect of weight gain. Significant changes in LDL-C, LDL particle concentrations, and LDL size were not observed.
Limitations
Because this was a randomized clinical trial of smoking cessation interventions, there were no nonsmoking controls; so we cannot determine the extent to which lipoprotein values normalized after smoking cessation. In smoking cessation studies, it is common for subjects who relapse to drop out or miss follow-up visits. [25] [26] [27] In our study, 38.6% of subjects did not return for their 1-year follow-up visit, which is consistent with the 30% to 43% 1-year dropout rates reported in other recent clinical trials of smoking cessation pharmacotherapy. 26, 27 Subjects who did not attend the follow-up visit had similar age, sex, and race distributions to those who did return; and they smoked a similar number of cigarettes per day at baseline. 15 Although significant efforts were made to recruit racially diverse participants, only16% of the study cohort was nonwhite. In addition, changes in alcohol use and physical activity levels were not included in the analysis because 1-year follow-up data were not yet coded for analysis. Alcohol use and exercise can increase HDL-C levels. Smoking cessation is not associated with increased exercise levels; however, we cannot exclude the possibility that the increases in HDL we observed among abstainers were related to increased alcohol intake. Most smoking cessation trials have not systematically evaluated alcohol use. 38 Smoking cessation studies that did evaluate alcohol use have had conflicting results 39, 40 ; however, our statistical models did not show that baseline exercise levels or alcohol use independently predicted changes in HDL parameters. Although LDL particles and LDL-C did not change significantly with smoking cessation, we did not measure oxidized LDL levels.
Conclusion
In this large, prospective, contemporary study of current smokers, smoking cessation improved HDL-C, total HDL, and large HDL particle concentrations, despite weight gain. These findings were especially strong in women. Smoking cessation, not baseline smoking intensity, predicted increased HDL parameters. These findings suggest that an increase in HDL may mediate some of the reduced CVD risk observed after smoking cessation. M. C. Fiore: Over the last 3 years, Dr Fiore has served as an investigator in research studies at the University of Wisconsin that were funded by Pfizer, GlaxoSmithKline, and Nabi Biopharmaceuticals. In 1998, the University of Wisconsin appointed Dr Fiore to a named Chair funded by an unrestricted gift to UW from Glaxo Wellcome.
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